- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024$21.7 (-1.05%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024$19.03Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023$19.64 (-1.13%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023$27.16Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023$27.94Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023$25.25Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019Earnings
Q1 2022 BioArctic AB Earnings Call Transcript
Welcome to BioArctic's Q1 Report 2022. Afterwards, there will be a question-and-answer session. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please begin your meeting.
()-
Good morning, and welcome to BioArctic's presentation from the first quarter. I'm sorry about the technical issues. I'm Gunilla Osswald, I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson.
I will give an update on lecanemab and some recent highlights in Alzheimer's disease. The Alzheimer's disease field is progressing really well with both lecanemab and some other treatments and with diagnostic tools, such as blood-based biomarkers. I think that it looks very promising for lecanemab. And this year will be very exciting for us with the lecanemab Phase III readout in Alzheimer's disease during the autumn and potentially an accelerated approval in the U.S. And I will talk more about that here today. And of course, I will also mention the recent
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)